Erlotinib is an antitumor drug of the new generation, a potent inhibitor of epidermal growth factor receptor tyrosine kinase that is responsible for the intracellular phosphorylation of epidermal growth factor, the expression of which is observed on the surface of both normal and tumor cells. Inhibition of epidermal factor receptor phosphotyrosine inhibits the growth of tumor cell lines and/or leads to their death.
Erlotinib user’s manual
Erlonat is used for:
– locally advanced or metastatic non-small cell lung cancer after failure of one or more chemotherapy regimens;
– Locally distributed inoperable or metastatic pancreatic cancer as 1st line therapy in combination with gemcitabine.
The drug is taken orally 1 p / day at least 1 hour before or 2 hours after eating. With non-small cell lung cancer, the drug is prescribed 150 mg daily, long-term.
In pancreatic cancer – 100 mg daily, for a long time in combination with gemcitabine. If signs of disease progression appear, therapy should be discontinued. With caution should prescribe the drug to patients with impaired liver function. Safety and efficacy in patients with hepatic insufficiency, renal dysfunction, and patients under the age of 18 years have not been studied. If necessary, dose adjustment is recommended to be reduced gradually, each time by 50 mg.
Side effects include:
On PS: anorexia, diarrhea, vomiting, stomatitis, dyspepsia, abdominal pain; gastrointestinal bleeding (some of which were associated with concomitant use of warfarin or NSAIDs), liver dysfunction (including increased ALT, ACT, bilirubin), mostly transient, mild or moderate severity, or associated with liver metastases.
From the side of the organ of vision: conjunctivitis, dry keratoconjunctivitis; keratitis, a case of transition to the corneal ulcer was revealed.
From the DS: cough, shortness of breath; nose bleed; interstitial lung diseases (interstitial pneumonia, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory distress syndrome and pulmonary infiltration, including cases with fatal outcome).
On the central nervous system and peripheral NA: headache, neuropathy, depression.
Dermatological reactions: rash, alopecia, dry skin, itching.
Other: fever, fatigue, chills, severe infections (with or without neutropenia), pneumonia, sepsis, fibrous inflammation of the subcutaneous tissue, weight loss.
The drug can not be used: during pregnancy; during lactation; with increased sensitivity to erlotinib or to any component of the drug. With caution should prescribe the drug in violation of liver function, patients under the age of 18 years.
The use of erlotinib with other drugs can lead to the following consequences: inhibitors of the isoenzyme CYP3A4 (ketoconazole, etc.) reduce the metabolism of erlotinib and increase its concentration in plasma; inducers of the isoenzyme CYP3A4 (rifampicin, etc.) increase the metabolism of erlotinib and significantly reduce its concentration in the plasma. With the simultaneous use of erlotinib with warfarin and other coumarin derivatives, there was an increase in MHO and bleeding, including gastrointestinal bleeding, some of which were associated with the introduction of warfarin.
Keep the drug in a dry place, protected from sun and inaccessible to children, at a temperature of 15 to 30 ° C. Date of manufacture and shelf life are indicated on the packaging.
Questions and answers of the customers
There are no questions yet, be the first to ask something for this product.